Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029515 | 0.92 | KDM4E (0.44) | KDM4EKMT2AALDH1A1MEN1DDB1 | |
| SCHEMBL14859444 | 0.79 | HSD11B1 (0.37) | KDM4EKMT2AALDH1A1MEN1HSD11B1 | |
| SCHEMBL31010265 | 0.76 | EPHX2 (0.42) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL2629313 | 0.67 | BCHE (0.35) | KDM4EKMT2AALDH1A1DDB1CRBN | |
| SCHEMBL2767111 | 0.65 | ALDH1A1 (0.40) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL20260854 | 0.65 | KDM1A (0.36) | KDM4EKMT2AALDH1A1DDB1CRBN | |
| SCHEMBL31010375 | 0.63 | DDB1 (0.44) | KDM4EKMT2AALDH1A1DDB1CRBN | |
| SCHEMBL2767113 | 0.63 | ALDH1A1 (0.38) | KDM4EKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL31289282 | 0.62 | P2RX7 (0.32) | KMT2ADDB1CRBNSMN1; SMN2OPRM1 | |
| SCHEMBL31010284 | 0.62 | DDB1 (0.43) | KMT2ADDB1CRBNSMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | GRUENENTHAL GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | SCN8A, SCN10A, SCN7A | KDM4E 3842/4885KMT2A 2923/4885ALDH1A1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.